Plain-English translation of NCT04414475 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether , a new medication, works well when combined with other drugs to treat multiple myeloma that has become resistant to multiple previous treatments. Researchers want to understand how effective and safe this medication combination is in patients whose cancer has stopped responding to standard therapies. The study compares a few different schedules and combinations to find the best approach.
Multiple myeloma is a blood cancer that often comes back or becomes resistant to treatments over time, leaving patients with few good options. This medication works by a different mechanism than many existing drugs, so researchers believe it may help people whose cancer has stopped responding to other therapies.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will take oral medication (tablets by mouth) on a schedule that repeats every 28 days—either twice per week on certain days or once per week, depending on which treatment group you're assigned to. You will have regular clinic visits to check your blood work, assess how you're responding to treatment, and monitor for any side effects. The study will continue until your cancer progresses, you experience unacceptable side effects, or you decide to stop.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
Greece
Israel